Arvinas Competitors
| ARVN Stock | USD 13.65 0.18 1.30% |
Arvinas vs Erasca Correlation
Poor diversification
The correlation between Arvinas and ERAS is 0.61 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Arvinas and ERAS in the same portfolio, assuming nothing else is changed.
Moving together with Arvinas Stock
Moving against Arvinas Stock
As of the 4th of February 2026, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.27. At this time, Arvinas' Fixed Asset Turnover is very stable compared to the past year. As of the 4th of February 2026, Asset Turnover is likely to grow to 0.23, while Total Assets are likely to drop about 802.9 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arvinas' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arvinas Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Arvinas and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Arvinas and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Arvinas does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Arvinas Stock performing well and Arvinas Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Arvinas' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| VALN | 2.20 | 0.03 | 0.00 | 0.57 | 2.35 | 4.83 | 15.59 | |||
| AVBP | 2.96 | 0.32 | 0.10 | 0.47 | 3.00 | 6.71 | 18.12 | |||
| DAWN | 4.35 | 0.87 | 0.21 | 1.53 | 3.61 | 13.81 | 39.62 | |||
| ATXS | 0.85 | 0.08 | 0.02 | (0.30) | 1.00 | 2.11 | 6.54 | |||
| REPL | 2.58 | (0.47) | 0.00 | (0.78) | 0.00 | 5.56 | 14.00 | |||
| MGTX | 2.52 | (0.19) | 0.00 | (0.07) | 0.00 | 5.08 | 14.00 | |||
| IOVA | 4.13 | 0.57 | 0.13 | 2.92 | 3.93 | 11.81 | 37.34 | |||
| GERN | 2.81 | 0.27 | 0.10 | 0.16 | 2.84 | 7.76 | 16.99 | |||
| DNA | 3.35 | (0.39) | 0.00 | 1.98 | 0.00 | 8.16 | 28.96 | |||
| ERAS | 4.85 | 2.57 | 0.67 | (3.70) | 2.49 | 15.04 | 50.26 |
Cross Equities Net Income Analysis
Compare Arvinas and related stocks such as Valneva SE ADR, ArriVent BioPharma Common, and Day One Biopharmaceu Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| DAWN | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.9 M) | (32.6 M) | (36.1 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.1 M) | (194.9 M) | (50.2 M) | (72.9 M) | (94.3 M) | (84.8 M) | (80.6 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
| IOVA | (57.1 K) | (25.7 M) | (3.3 M) | (25.4 M) | (12 M) | (27.7 M) | (52.9 M) | (92.1 M) | (123.6 M) | (187.1 M) | (259.6 M) | (327.8 M) | (389.9 M) | (444 M) | (372.2 M) | (335 M) | (318.2 M) |
| GERN | (10.7 M) | (96.9 M) | (68.9 M) | (38.4 M) | (35.7 M) | 46 K | (29.5 M) | (27.9 M) | (27 M) | (63.6 M) | (75.6 M) | (116.1 M) | (141.9 M) | (184.1 M) | (174.6 M) | (157.1 M) | (149.3 M) |
| DNA | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (126.6 M) | (1.8 B) | (2.1 B) | (892.9 M) | (547 M) | (492.3 M) | (516.9 M) |
| ERAS | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (101.7 M) | (122.8 M) | (242.8 M) | (125 M) | (161.7 M) | (145.5 M) | (152.8 M) |
Arvinas and related stocks such as Valneva SE ADR, ArriVent BioPharma Common, and Day One Biopharmaceu Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Arvinas financial statement analysis. It represents the amount of money remaining after all of Arvinas operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Arvinas Competitive Analysis
The better you understand Arvinas competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Arvinas' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Arvinas' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Arvinas Competition Performance Charts
Five steps to successful analysis of Arvinas Competition
Arvinas' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Arvinas in relation to its competition. Arvinas' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Arvinas in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Arvinas' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Arvinas, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Arvinas position
In addition to having Arvinas in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Arvinas Correlation with its peers. To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Pharmaceuticals sector continue expanding? Could Arvinas diversify its offerings? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Arvinas data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth (0.59) | Return On Assets | Return On Equity |
Understanding Arvinas requires distinguishing between market price and book value, where the latter reflects Arvinas's accounting equity. The concept of intrinsic value - what Arvinas' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Arvinas' price substantially above or below its fundamental value.
Understanding that Arvinas' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arvinas represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Arvinas' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.